is semaglutide safe for liver and Enzymes: Effects, Monitoring, and Safety Focus on Semaglutide 2.4 mg/week

Semaglutide is currently considered the most effective GLP-1 medication for weight management

Use within 30 days of first injection

Mechanistic studies examining the pathways related to GLP-1RA use with vestibular dysfunction are needed, particularly the role of GIP co-agonism in decreasing vestibular risk

Zepbound: The Same Story as Ozempic vs

A systematic review of the antidepressant effects of glucagon-like peptide 1 ( GLP-1 ) functional agonists: Further link between metabolism and psychopathology Special Section on Translational and Neuroscience Studies in Affective Disorders

Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation